Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06945315 · ClinicalTrials.gov registry record · Phase 3

SAFE Nerve Sparing Guided by Micro-ultrasound (MUS)

A Phase 3 study of Prostate Cancer and Erectile Dysfunction, sponsored by Icahn School of Medicine at Mount Sinai.

Recruiting
Registry status
Phase 3
Development phase
196
Enrollment target
1
Study location

NCT06945315: Recruiting Phase 3 study of Prostate Cancer and Erectile Dysfunction, sponsored by Icahn School of Medicine at Mount Sinai.

NCT06945315 is a Phase 3 study of Prostate Cancer and Erectile Dysfunction that is actively recruiting participants, run by Icahn School of Medicine at Mount Sinai. The registered enrollment target is 196 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (68% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06945315, a Phase 3 study of Prostate Cancer and Erectile Dysfunction, is actively recruiting participants, sponsored by Icahn School of Medicine at Mount Sinai.

RECRUITING
Registry status
Phase 3
Development phase
196 participants
Enrollment target
1
Study location

Study Summary

Robotic-assisted radical prostatectomy (RALP) has become the standard of care in the management of localized prostate cancer. However, post-prostatectomy erectile dysfunction (ED) and urinary incontinence still pose a challenge that adversely affects the patient's quality of life. Hydrodissection (HD) was introduced in 1987 in the medical field and it was tested for the first time during a retropubic radical prostatectomy back in 2005. Since then, research has indicated an improvement in erectile function results, presumably because of a less traumatic neural dissection and a decreased risk of neuropraxia. In an effort to achieve a balance between oncological excision and functional preservation, prostate surgery is evolving to incorporate intraoperative real-time evaluation of extracapsular extension. Recently, a micro-ultrasound operating at 29 MHz has been introduced. It provides a resolution down to 70 μ to assess the glandular pattern and cellular density of the prostatic tissue. Given the experience in more than a thousand cases with this technology, and the growing literature showing promising results in the detection and staging of prostate cancer; the researchers decided to implement this tool as guidance for hydrodissection of the layers of the lateral prostatic fascia. Robotic-Assisted Laparoscopic Prostatectomy and SAFE (Saline assisted fascial engorgement) nerve preservation guided by Microultrasound (MUS) is a prospective randomized controlled trial designed to evaluate the impact of normal saline solution hydrodissection (HD) on erectile function outcomes after RALP. This innovative approach consists of a transrectal ultrasound-guided HD using a high-resolution Microultrasound (MUS) (ExactVu micro-ultrasound, Exact Imaging, Markham, Canada). The technique will be applied to those patients who undergo grade 1, 2, or 3 NS approach taking into account the grading system proposed by Tewari et al. The hypothesis is that the SAFE technique could minimize

Primary Outcome

The Sexual Health Inventory for Men (SHIM) is a five-question, abbreviated, validated questionnaire derived from the International Index of Erectile Function questionnaire. It is widely used by urologists to evaluate efficacy of ED treatments. It is graded on a scale of 1-25, with higher scores indicating no signs of erectile dysfunction.

Interventions

  • PROCEDURE RALP (Robotic-assisted radical prostatectomy)
  • DRUG SAFE (Saline assisted fascial engorgement)

Study Locations (1)

New York

  • Mount Sinai Hospital - New York

Trial Details

FieldValue
Enrollment Target 196 participants
Start Date 2023-11-14
Est. Completion 2027-07-14
Phase Phase 3

What NCT06945315 shows while recruiting

NCT06945315 is an interventional study that assigns participants to a tested intervention. The registered 196 participants enrollment target is mid-sized for trials with a published cap, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (68% lower).

The record links to 2 conditions, with Prostate Cancer appearing as the primary indexed condition, and to 2 interventions - of which RALP (Robotic-assisted radical prostatectomy) is the first listed.

NCT06945315 reports a single indexed study location in New York.

Frequently Asked Questions

What is clinical trial NCT06945315 about?

NCT06945315 is a clinical study titled "SAFE Nerve Sparing Guided by Micro-ultrasound (MUS)". Robotic-assisted radical prostatectomy (RALP) has become the standard of care in the management of localized prostate cancer. However, post-prostatectomy erectile dysfunction (ED) and urinary incontinence still pose a challenge that adversely affects the patient's quality of life. Hydrodissection (H...

What is the current status of trial NCT06945315?

This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 196 participants. The study started on 2023-11-14. Estimated completion is 2027-07-14.

What conditions does trial NCT06945315 study?

This clinical trial studies the following conditions: Prostate Cancer, Erectile Dysfunction.

What interventions are being tested in trial NCT06945315?

The interventions under investigation include: RALP (Robotic-assisted radical prostatectomy) (PROCEDURE), SAFE (Saline assisted fascial engorgement) (DRUG).

Who is sponsoring clinical trial NCT06945315?

This trial is sponsored by Icahn School of Medicine at Mount Sinai, which has 708 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06945315 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Prostate Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06945315's enrollment target sits among peer trials

196 234th of 735 higher than 502 of 735 other Prostate Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Prostate Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02822768 · 196 participants · NA

    Packing Versus no Packing for Cutaneous Abscess

  • NCT04250259 · 196 participants · Phase 2

    SAMe Trial for Patients With Alcoholic Cirrhosis

  • NCT05142592 · 196 participants · Phase 1

    Phase1/2a Study for IPG7236 in Patients With Advanced Solid Tumors

  • NCT05317832 · 196 participants · Phase 2

    Using Smartphones to Improve Physical Activity Levels of Individuals With Spinal Cord Injury

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06945315, the US trial registry maintained by the National Library of Medicine. NCT06945315 (mid enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.